Search Within

Department of Medicine

Formats
  1. Journal Article (19626)
  2. Meeting Abstract (16084)
  3. Review (1160)
  4. Book Section (934)
  5. Editorial (612)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22375)
  2. Hematologic Malignancies, Division of (13310)
  3. Center for Hematologic Malignancies (11084)
  4. GSK Faculty (10659)
  5. Survivorship Research (9357)
  6. Division of Subspecialty Medicine (7562)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1167)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4217)
  3. American Society of Hematology (4004)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2306)
  6. Nature Publishing Group (2122)

More Publishers

Results (39720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Epcoritamab + R2 regimen and responses in patients with high-risk follicular lymphoma, regardless of POD24 status
    Meeting Abstract

    Merryman, R. W.; Belada, D.; Sureda, A.; Leppä, S.; Vermaat, J. S. P.; Holte, H.; Hutchings, M.; Lugtenburg, P.; de Vos, S.; Abrisqueta, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in R/R MCL: Primary analysis results from the mcl cohort of the single-arm, multicenter, phase I seamless design TRANSCEND NHL 001 study
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • A phase III, randomized, double-blind, study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Salles, G.; Shah, H.; Leonard, J. P.; Szanto, A.; Chen, J.; Bannerji, R.; Morschhauser, F.; Nastoupil, L. J.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Final results from the phase II L-MIND study
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Phase III trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2
    Meeting Abstract

    Sehn, L.; Chamuleau, M.; Lenz, G.; Clausen, M.; Haioun, C.; Izutsu, K.; Davies, A.; Zhu, J.; Oki, T.; Szafer-Glusman, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase II study results of lisocabtagene maraleucel (liso-cel) in patients with R/R follicular lymphoma (FL)
    Meeting Abstract

    Nastoupil, L. J.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K. I.; Dreyling, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Responses with asciminib continue to deepen over time in patients with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase III ASCEMBL study
    Meeting Abstract

    Mauro, M.; Hochhaus, A.; Hughes, T.; Rea, D.; Boquimpani, C.; Minami, Y.; Apperley, J.; Garcia-Gutiérrez, V.; Kapoor, S.; Espurz, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save